Addressing Unmet Needs for Cholangiocarcinoma & Myeloid Lymphoid Neoplasms
Phase 2 FIGHT-203 Study: Pemigatinib in Pts With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
By
ASH 2022 Conference Coverage
FEATURING
Alessandro Vannucchi
By
ASH 2022 Conference Coverage
FEATURING
Alessandro Vannucchi
Login to view comments.
Click here to Login
Addressing Unmet Needs for Cholangiocarcinoma & Myeloid Lymphoid Neoplasms